The FDA has granted a priority review to a supplemental biologicslicense application for frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.
More From BioPortfolio on "FDA Grants Priority Review for Full Approval of Frontline Pembrolizumab Combo in NSCLC"